TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immix Biopharma ( (IMMX) ) has issued an update.
On June 20, 2025, Immix Biopharma, Inc. held its Annual Meeting where stockholders representing 72.1% of the voting shares were present. During the meeting, the stockholders elected directors to serve until the next annual meeting and ratified the appointment of Crowe LLP as the independent registered public accounting firm for the year ending December 31, 2025.
The most recent analyst rating on (IMMX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Average Trading Volume: 210,574
Technical Sentiment Signal: Buy
Current Market Cap: $62.45M
Learn more about IMMX stock on TipRanks’ Stock Analysis page.